# Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Source: https://onco.cc/trials/nct04068597/  
OnCo record `nct04068597` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pomalidomide, Dexamethasone, Azacitidine in hodgkin lymphoma and non-hodgkin lymphoma, run by CellCentric Ltd., now recruiting.

## Summary

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies is a phase 1/2 interventional study registered as NCT04068597 by CellCentric Ltd., with 250 participants planned, started 2019-08-09 and due to reach its primary completion in 2027-03-31. Interventions recorded: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax. Conditions listed: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04068597
- Phase: 1/2
- Setting: An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
- Sponsor: CellCentric Ltd.
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT04068597: https://clinicaltrials.gov/study/NCT04068597

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Ixazomib](https://onco.cc/drugs/ixazomib/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct04068597.json